[go: up one dir, main page]

WO2019002321A1 - Dispositif de contrôle de qualité intégré - Google Patents

Dispositif de contrôle de qualité intégré Download PDF

Info

Publication number
WO2019002321A1
WO2019002321A1 PCT/EP2018/067162 EP2018067162W WO2019002321A1 WO 2019002321 A1 WO2019002321 A1 WO 2019002321A1 EP 2018067162 W EP2018067162 W EP 2018067162W WO 2019002321 A1 WO2019002321 A1 WO 2019002321A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
analyte
sample
flow path
inlet port
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/067162
Other languages
English (en)
Inventor
Sofia Rodrigues VAZ
Solange Almeida PACHECO
Rosalina Varandas FERNANDES
Maria João Santos Da Costa Leite COSTA
João Tiago Dos Santos FERNANDES
Filipe Da Conceição Fernandes THOMAZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosurfit SA
Original Assignee
Biosurfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1710490.2A external-priority patent/GB201710490D0/en
Application filed by Biosurfit SA filed Critical Biosurfit SA
Publication of WO2019002321A1 publication Critical patent/WO2019002321A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/143—Quality control, feedback systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/148—Specific details about calibrations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0803—Disc shape
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/087—Multiple sequential chambers

Definitions

  • the disclosure relates to quality control for a batch of assay devices.
  • Modern assays and tests are often provided in the form of a microfluidic device (or cartridge) for use with a reader.
  • the device allows a sample to be introduced and may carry other liquids in storage arrangements such as blister packs so that they can also be introduced into the device, for example by pressing on the blister pack.
  • the device is then inserted into a reader for processing the sample and obtaining a read out of the assay, for example to determine the concentration of a analyte, such as proteins (e.g., glycated haemoglobin, C- Reactive Protein), enzymes (e.g., AST, ALT), hormones (e.g., TSH), sugars (e.g., glucose), lipids (e.g., cholesterol, triglycerides) and the like, in a sample.
  • proteins e.g., glycated haemoglobin, C- Reactive Protein
  • enzymes e.g., AST, ALT
  • hormones e.g., TSH
  • sugars e.g., glucose
  • lipids e.g., cholesterol, triglycerides
  • control reagents provided in liquid form are expensive and have a very limited shelf-life once opened, resulting in a considerable expense and inconvenience for the user.
  • control reagents provided in solid form need to be solubilized or suspended in a liquid carrier (e.g., water or a buffer) before use, which represents an inconvenience for the user.
  • a batch of assay devices comprising a quality control device, a quality control device and a method of manufacturing a batch of assay devices comprising a quality control device, as well as a method of using the quality control device to carry out quality control are disclosed.
  • a batch of devices comprising a sample inlet port, a liquid inlet port and a liquid handling structure defining a detection chamber and a flow path between the liquid inlet port and the detection chamber.
  • a reagent for interacting with an analyte in a sample introduced into the device through the sample inlet port is disposed in each device to enable detection of the analyte in the detection chamber.
  • At least one of the devices is configured as a quality control device and comprises a deposit of the analyte in the flow path to reconstitute a reconstituted sample of known concentration for detection in the detection chamber when the liquid flows along the flow path in the at least one device and the remaining devices do not comprise the deposit of the analyte.
  • the assay devices do not include the deposit of analyte but are otherwise substantially identical to a quality control device.
  • the assay devices may differ from the quality control device, for example, in that the sample port, which is not needed in a quality control device, is permanently sealed in the quality control device, while it may be sealable once a sample has been applied in the remainder of the batch (although the port may also be initially open and sealable in the quality control device). Further differences may, for example, relate to details of any surface marking or decoration applied to the devices or packaging in which they are packaged, for example to identify the quality control device as such.
  • the reagent may have specificity for the analyte, for example specifically bind to the analyte.
  • the reagent may be an antibody or enzyme, mix of antibodies and enzymes, etc., and the analyte may be an antigen or set of antigens, protein or carbohydrate molecule to which the antibody(ies) specifically binds or the enzyme(s) is specific for.
  • Other reagents may be used in the assay, for example as discussed below, and may be involved in the assay detection, such as in the case of fluorophores.
  • the reagent specific to the analyte may be immobilised or bound to a physical support such as a surface of the device or carrier particles, such as latex beads, for example, which can also be considered as reagents.
  • the analyte may bind to a support like latex beads and the antibodies bind to the analyte-support complex.
  • antibody to target binding can be detected by the resulting agglutination of the latex beads with attached analyte and antibodies.
  • antibodies are examples of probe molecules specifically binding to target molecules such as antigens.
  • the disclosed devices and methods are equally applicable to any type of specific reagent, antibody, probe molecule, stain, fluorophore or otherwise. It will be appreciated that the disclosure is not limited to a single specific reagent but that the assay may involve more than one specific reagent. Reference to "a specific reagent" does not exclude the presence and use of additional specific reagents.
  • the reagent or reagents may be provided in dry form in the flow path or may be provided in a liquid storage arrangements, such as a blister pack, secured adjacent the liquid inlet port.
  • Reagents may comprise particle suspensions, functionalised latex beads or nanoparticles, reaction mixtures, one or more buffers, saline solution, antibodies, enzymes or a combination thereof. Latex beads or nano-particles and a functionalising reagent may be stored separately in the device and the latex beads or nanoparticles may be functionalised during the microfluidic protocol when the device is used.
  • the analyte may comprise a biomolecule or a mixture of biomolecules and the analyte deposit may further comprise one or more of: one or more stabilisers selected from glucose, sucrose, reducing monosaccharide sugars and reducing disaccharide sugars; a buffer; one or more preservatives (for example, an antimicrobial agent); serum; a serum matrix; and blood.
  • one or more stabilisers selected from glucose, sucrose, reducing monosaccharide sugars and reducing disaccharide sugars
  • a buffer for example, one or more preservatives (for example, an antimicrobial agent); serum; a serum matrix; and blood.
  • the deposit Prior to use of a device by introduction of a fluid, for example, to carry out an assay, the deposit may be a dry deposit substantially free from solvent, for example a liquid sample dried in situ or a deposit of an already dried substance. Alternatively, the deposit may be in a gel state, for example where the analyte comprises trehalose
  • the deposit may be imbibed in an absorbent material, such as filter paper, or coated on a carrier material, such as polymer substrate.
  • the assay may be to detect a characteristic, for example concentration, of an analyte or to detect the presence of the analyte.
  • the assay device is for measuring a concentration of particular biomolecule
  • the deposit comprises a sample of said biomolecule, thereby providing a control run for the assay.
  • the assay device is provided with an integrated control. This may be of particular advantage when a batch of devices is produced, one of which comprising the integrated analyte deposit, as it provides a control run for the batch of assays. It may also provide for calibration of the apparatus used to measure the result of the assay.
  • the analyte may be deposited such that upon pick up of the analyte by the fluid flowing through the device, sufficient control analyte, preferably of a known concentration is present in the liquid to provide a control for the analyte.
  • the or each device comprises a body defining an internal liquid handling structure.
  • the body defines a first aperture in an external surface thereof to provide a liquid inlet port to the liquid handling structure and a second aperture in the external surface to provide a sample inlet port to the liquid handling structure, wherein the sample inlet port is sealed or sealable.
  • the device comprises liquid storage arrangement storing a liquid and secured to the external surface of the body overlapping the first aperture to dispense the liquid through the first aperture when a pressure exceeding a threshold pressure is applied to the liquid storage arrangement.
  • the device further comprises a reagent specific to the analyte to enable detection of the analyte in the assay.
  • the liquid handling structure defines a detection chamber to receive liquid from the liquid inlet port and enabling detection of a signal indicative of a reaction between the analyte and the reagent and a first fluid flow path between the liquid inlet port and the detection chamber.
  • a deposit comprising the analyte is deposited within the first fluid flow path.
  • the liquid flows along the flow path it interacts with the deposit to reconstitute a sample of known analyte concentration to interact with the reagent, for example in the detection chamber or as liquid flows from the liquid receiving chamber to the detection chamber.
  • the first liquid flow path and a second liquid flow path from the sample inlet port to the detection chamber join in a common flow path common to both the first and second flow paths, and the deposit comprising the analyte is disposed in the common flow path.
  • a device configured to carry out quality control for an assay to detect an analyte.
  • a device body defines an internal liquid handling structure, a first aperture in an external surface of the body to provide a liquid inlet port to the liquid handling structure and a sample inlet port to the liquid handling structure, wherein the sample inlet port is sealed or sealable.
  • the inlet port may be permanently sealed by not providing a corresponding aperture in the external surface, or an aperture may be provided but (permanently or reversibly) sealed.
  • the sample inlet port may be configured as for an assay (rather than quality control device), in association with a sealed or sealable aperture in the external surface.
  • a liquid storage arrangement storing a liquid is secured to the external surface of the body overlapping the first aperture to dispense the liquid through the first aperture when a pressure exceeding a threshold pressure is applied to the liquid storage arrangement.
  • the device comprises a reagent specific to the analyte to enable detection of the analyte and the liquid handling structure defines a detection chamber to receive liquid from the liquid inlet port and enabling detection of a signal indicative of a reaction between the analyte and the reagent.
  • the liquid handling structure further defines a detection chamber to receive liquid from the liquid inlet port and enable detection of a signal indicative of a reaction between the analyte and the reagent.
  • the liquid handling structure also defines a first liquid flow path from the liquid inlet port to the detection chamber and a second liquid flow path from the sample inlet port to the detection chamber.
  • the first and second liquid flow paths join in a common flow path to the detection chamber and a deposit comprising the analyte is disposed in the common liquid flow path, wherein when the liquid flows along the common flow path it interacts with the deposit to reconstitute a sample of known analyte concentration to interact with the reagent.
  • the similarity of the assay and quality control devices is increased, since the portion of the first flow path not exposed to analyte in the assay device remains so in the quality control device, which may improve quality control.
  • the increased similarity facilitates the aim of the quality control device to control the quality of a batch of substantially identical assay devices.
  • the device or devices may be configured for rotation about an axis of rotation to drive liquid flows in the device.
  • the deposit may be disposed in an unvented chamber of the liquid handling structure, which may be configured to enable the liquid to be moved back and forth repeatedly between the unvented chamber and a portion of the liquid handling structure upstream of the unvented chamber to pick up the deposit with the liquid and mix the liquid by varying the speed of rotation (thereby changing the balance between a centrifugal force and a pressure in the unvented chamber).
  • the device or devices may be a microfluidic device(s).
  • the term "microfluidic" is referred to herein to mean devices having a fluidic element such as a reservoir or a channel with at least one dimension below 1 mm.
  • the device may be configured to handle volumes of liquid on the scale of nanolitres to microlitres or up to 100 -microliters. Some but not necessarily all the structures on such a device may be microfluidic.
  • the device or devices comprise a feature which defines the axis of rotation and which is configured to be coupled to a rotational element to drive rotation of the device.
  • the device or devices may be configured as a centrifugal disc, such as a microfluidic disc.
  • the device or devices, disc-shaped or otherwise, may comprise a central hole which is configured to engage with a spindle of a drive system, the spindle being coupled to a motor for driving rotation of the spindle, which in turn drives rotation of the engaged device.
  • vented and unvented as used herein are used such that a vented chamber is connected to the atmosphere external to the device or a closed air circuit so that pressure can equilibrate as liquid flows in or out of respective ports, for example inlet and outlet ports, of the vented chamber.
  • an unvented chamber is neither connected to external air nor to a closed air circuit such that, once liquid fills any inlet and outlet ports of the unvented chamber any difference in respective flow rates in and out of the unvented chamber leads to a change in pressure in the unvented chamber.
  • the only fluid flow paths in or out of the unvented chamber are through one or more liquid ports part of a liquid flow circuit of the device.
  • cavities referred to herein may be described as vented or unvented, as the case may be.
  • level is used in relation to a chamber or other liquid containing structure, it will be understood that this does not necessarily refer to a straight level as would be observed in a chamber filled with liquid under gravity, but that the term includes curved levels which may be curved due to a centrifugal force acting on the liquid or due to surface tension effects.
  • level refers to a geometric locus, e.g. relative to a centre of rotation.
  • any reference to a fill level of a liquid containing structure (e.g. a chamber or conduit) rising will be understood to refer to the liquid level moving radially inwards, towards the axis of rotation.
  • any reference to a fill level of a liquid containing structure (e.g. a chamber or conduit) falling will be understood to refer to the liquid level moving radially outwards away from the axis of rotation.
  • reference to a structure 'A' being disposed radially inwards of a structure 'B' should be taken to mean that a distance between structure ⁇ and the axis of rotation of the device is less than a distance between structure 'B' and the axis of rotation of the device.
  • reference to a structure ⁇ being disposed radially outwards of a structure 'B' should be taken to mean that a distance between structure 'A' and the axis of rotation of the device is greater than a distance between structure 'B' and the axis of rotation of the device. It will be understood that reference to a structure extending radially inwards should be taken to mean that the structure extends towards the axis of rotation. Equally, it will be understood that reference to a structure extending radially outwards should be taken to mean that the structure extends away from the axis of rotation.
  • a method of manufacturing a batch of devices each configured to carry out an assay wherein each device comprises a sample inlet port, a liquid inlet port and a liquid handling structure defining a detection chamber a flow path between the liquid inlet port and the detection chamber and a reagent for interacting with an analyte in a sample introduced into the device through the sample inlet port to enable detection of the analyte in the detection chamber.
  • the method comprises manufacturing the batch of devices and depositing a sample of the analyte in the flow path of a quality control device of the batch of devices to reconstitute a reconstituted sample of known concentration for detection in the detection chamber when the liquid flows along the flow path in the quality control device.
  • the method comprises drying the deposited sample or depositing the sample in dry form.
  • the sample may comprise an amount of analyte and the liquid handling structure is configured to meter an amount of liquid flowing along the flow path to reconstitute the reconstituted sample to a known concentration of analyte.
  • the deposited sample may comprise a biomolecule, for example in a concentration of about 0.01 ng/ml to about 1 g/dl and the volume.
  • the sample may be deposited in liquid form and the volume of the deposited sample may be 1 nanolitre to 100 microlitres.
  • the method may comprise depositing the sample in liquid form and drying the sample in situ.
  • the device may be configured as disclosed herein.
  • a method of carrying out quality control for a batch of devices as disclosed herein or manufactured according to a method disclosed herein comprises causing the liquid to reconstitute the deposited sample in the quality control device, performing the assay to obtain a result of the assay and comparing the result to an expected result.
  • causing the liquid to reconstitute the deposited sample may comprise applying a mechanical pressure to the exterior of the quality control device to introduce the liquid into the quality control device, introducing the device into a reader and rotating the device inside the reader according to a rotation protocol defined for the batch of devices.
  • Obtaining the result of the assay may comprise analysing a signal from the quality control device.
  • the signal may be indicative of light reflected from or transmitted through the detection chamber.
  • the method may comprise adjusting one or more parameters of the reader based on the comparison between the result and the expected result, for example to calibrate the reader or making other adjustments, for example bias adjustments.
  • a method of manufacturing a device as described herein for carrying out an assay to detect a characteristic of an analyte comprising: providing a substrate defining a liquid handling structure on a surface of the substrate, wherein the liquid handling structure comprises a liquid receiving chamber and a fluid flow path between the liquid receiving chamber and a detection chamber; depositing a sample of a reagent comprising the analyte having a characteristic on a portion of the surface of the substrate within the fluid flow path; drying the sample of a reagent to form a reagent deposit on the surface of the substrate; and sealing the substrate with a seal to enclose the surface defining a liquid handling structure within which the reagent deposit is dried.
  • the seal used to seal the substrate may be a second substrate or a film. Disclosed embodiments may use this process to manufacture a batch of disks.
  • Figure 1 illustrates a centrifugal microfluidic device
  • FIG. 2 illustrates a specific flow path
  • FIG. 3 illustrates a specific implementation of the centrifugal microfluidic devices
  • Figure 4 illustrates a device reader
  • Figure 5 illustrates a method of operation of the device reader.
  • a centrifugal microfluidic device 100 comprises a sample inlet port 102, a liquid inlet port 104 and a liquid storage arrangement 106, such as a blister pack, secured to the device 100 in a fully overlapping relationship with the liquid inlet port 104.
  • a liquid storage arrangement 106 such as a blister pack
  • the liquid may be a buffer and/or a reagent solution to be mixed with a sample introduced into the device through sample inlet port 102.
  • the sample inlet port 102 is sealable once the sample has been introduced and the device comprises an internal air circuit to provide pressure equilibration to vented structures in the device as liquid flows.
  • the sample inlet port 102, and in some embodiments a vent port connected to the internal air circuit, may be sealable with an adhesive flap provided separately or secured to the device 100.
  • reagents may be provided in dry form along the flow path 1 10 for processing and/or conditioning of the analyte, for example lysing blood cells in a blood sample.
  • the flow path 108 comprises a portion of a flow path between the sample inlet 102 and the detection chamber 1 12, that is there is a common flow paths for liquids from both ports.
  • the reagent(s) may be provided as one or more discrete dry reagent deposits along the flow path 108, arranged to provide pick-up of the reagent by the liquid (for example, a buffer). Pick-up of reagent may be achieved by rehydration, dissolution or re-suspension of reagent by the liquid or by digestion of reagent by an enzyme within the liquid. Accordingly, the reagent may be hydrophilic, water soluble and/or enzymatically degradable. Additional reagents may be provided, acting in combination or separately from the reagent, at adjacent or different positions along the flow path 108.
  • the device is configured so that liquid flows in the device are driven by centrifugal forces when the device is rotated and comprises a cut-out feature 1 14, in the fashion of a CD or DVD, to allow a spindle in a reader for the device 100 to engage the device 100 and rotate it about an axis of rotation, in this case centred on the feature 1 14.
  • the reader (not shown) is configured to rotate the device according to a temporal profile of rotation speed to drive liquid flows in the device in accordance with the specific assay protocol implemented in the device and comprises a reading arrangement comprising a light source and a light sensor to detect light from the light source that is transmitted through or reflected by the detection chamber 1 12.
  • Occurrence of a reaction between the reagent and the analyte in the device alters the light received from the detection chamber, so that the light sensor signal can be used infer the presence or a characteristic (such as concentration) of the analyte in a sample in the device 100.
  • the flow paths 108 and 1 10 are illustrated in Figure 1 in a highly schematic fashion and will in practice comprise various liquid handling elements, for example for processing the sample, such as separating the sample into phases, selectively flowing selected phases, mixing the sample with the liquid and with chemicals and other substances provided in dry form, metering a volume of the sample and/or liquid, producing aliquots, etc.
  • Batches of the device 100 are manufactured and are characterized and tested to produce calibration data for a reader.
  • Each device 100 is packaged in an individual packaging in some embodiments, in some advantageous embodiments in sealed vacuum pouches. These batches are distributed to customers for use with a reader in batches that may comprise all devices 100 in a manufacturing batch or subsets thereof.
  • Each batch distributed comprises one or more quality control devices that are now described in detail.
  • Each quality control device is identical to the other devices 100 in the batch, save for, of course, manufacturing tolerances and other inconsequential differences such as different surface decoration or packaging labeling. A further difference may be that, as will become clear, there is no need to provide for the sample port 102 to be sealable.
  • the sample port 102 is sealed, for example with an adhesive flap attached at manufacture or by providing only the internal structures corresponding to the sample port 102 with a corresponding cut-out providing access to the sample inlet port 102 being omitted from an external layer of the device 100 at the time of manufacture.
  • a yet further difference is that a deposit containing an amount of analyte (or a substance reacting with the reagent in substantially the same way as the analyte) is deposited in the flow path 108 at the time of manufacture, as indicated schematically by arrow 1 16 in Figure 1 .
  • the analyte is deposited in the common flow path common to liquid from both inlet ports.
  • the amount of analyte is chosen so that a sample of known concentration is reconstituted as a metered volume (metered in a metering chamber or in the liquid storage arrangement 106) of liquid flows in the flow path 108, without any sample being introduced into the device from outside.
  • the biomolecule may be isolated from human tissue.
  • the analyte deposit may be provided on a serum, blood or plasma based matrix or a buffer.
  • the deposit may further comprise additional excipients to provide for increased pick up or improved flow of the analyte within in the device.
  • the device may further comprise: a) one or more stabilisers selected from glucose, sucrose, reducing monosaccharide sugars and reducing disaccharide sugars; b) a buffer; c) one or more preservatives (for example, an antimicrobial agent) and d) serum or blood derivative.
  • the deposit may further comprise additional proteins or enzymes.
  • the sample and liquid inlet ports 102, 104 are connected to the vented chamber 202 by respective flow paths 1 10 and 206 that are illustrated schematically in Figure 2, which omits some details such as, for example, a metering structure in the flow path 206 to meter a volume of liquid coming from the liquid inlet port 104.
  • the vented chamber 202 is connected to the air circuit (not shown) by a vent conduit 208, to the unvented chamber 204 by a flow path 210 and to the detection chamber 1 12 by a flow control arrangement 212 and flow path 214.
  • the flow control arrangement 212 is configured to retain liquid in the vented chamber 202 until a time when it is desired to flow downstream, for example by means of controlling the profile of rotations speeds of the device.
  • a sample is introduced via sample port 102, the sample port 102 is sealed and the liquid storage arrangement 106 is ruptured to introduce the liquid into the device through the liquid inlet port 104.
  • the sample may, for example, be a lysed or a whole blood sample.
  • the device is then inserted into the reader for rotation in accordance with a speed profile to cause processing of the sample and liquid and a signal is then read out from the detection chamber 1 12.
  • a similar process is followed for a quality control or calibration run, although without the introduction of a sample, as the quality control sample is reconstituted inside the device 100 as liquid flows through the device 100.
  • the rotation profile comprises a portion of oscillating velocity timed to coincide with both liquids being present in the vented chamber 202, which cause the combined liquid to flow back and forth between the vented and unvented chambers 202, 204 due to the interaction of the time varying centrifugal force and pressure in the unvented chamber 204 as liquid is forced into it by an increasing centrifugal force and forced back out as a decreasing centrifugal force does not balance the pressure in the unvented chamber 204 leading to an expansion of the air compressed by previous liquid ingress and corresponding expulsion of liquid from the chamber 204.
  • a centrifugal microfluidic device 300 is configured for an assay to detect the HbA1 c (glycated haemoglobin) concentration in a blood sample. It will be appreciated that a device of a same or similar structure can implement a variety of assays of blood components and markers.
  • the device 300 comprises structural units A-E indicated by dashed outlines in Figure 3 implementing five corresponding functional blocks: (A) lysing a blood sample from sample inlet 102 and metering an aliquot of lysed blood; (B) metering two aliquots of buffer liquid comprising a suspension of latex beads from the liquid storage arrangement 106;(C) diluting the aliquot from block (A) with one of the aliquots of block (B); (D) diluting the dilution from block (C) with the other one of the aliquots of block (B); and (E) resuspending a dried antibody specific to HbA1 c to promote an agglutination reaction that is a function of antibody HbA1 c binding, so that a measure HbA1 c concentration can be detected based on a measurement of the turbidity of the liquid from block (E), measured in the detection chambers 312a, b.
  • a blood sample of about 5 microlitres to be investigated with the assay is introduced into the device 300 through the inlet port 102 and the device sealed with an adhesive flap.
  • the blood sample may be lysed when it comes into contact with hemolysing agent on re-suspension of the deposit of the hemolysing agent 314.
  • the user may choose to insert a lysed blood sample irrespective of the presence of a lysing agent in the device or, in some embodiments, the lysing agent may be omitted.
  • the device is introduced into the reader and a rotational protocol is executed to carry out the fluidic operations required to conduct the HbA1 c assay. Specifically, the following steps are carried out:
  • Step #1 Metering an aliquot of the lysed blood sample on structural block [A] and metering two separate aliquots of the liquid from the liquid storage arrangement in structural block [B].
  • Step #3 Metering a smaller aliquot of the diluted sample and further diluting it with the second aliquot of the liquid to reach the sample dilution required for the assay (e.g. 1 :2500). This step is executed in structural block [D].
  • Step #4 Re-suspending the dry deposit 318 of the reagent specific to the analyte with the final dilution of the sample to promote the latex agglutination reaction. This step is executed in structural block [E].
  • Step #5 Routing the reaction mixture to detection chambers 312a and 312b.
  • the assay reaction is then detected, for example followed in real-time using suitable detection means, as is well known in the art.
  • the device 300 When configured as an integrated quality control device, the device 300 contains the dry deposit of an analyte 216 downstream from the sample inlet port 102, for example in the unvented chamber 204 in block C.
  • the deposit of the hemolysing reagent 314 may not be required if, for example, the analyte is provided in the deposit readily available (i.e. not requiring any lysing step) and would need to be included in the flow path from the liquid storage arrangement 106 rather than in block A as in the assay device otherwise
  • the device is otherwise substantially identical as described above.
  • a user applies pressure to the liquid storage arrangement 106 to dispense the liquid into liquid receiving chamber 316 of the device 300.
  • the device is then introduced into the reader and the same rotational protocol is executed.
  • Step #1 no sample metering is required (although the corresponding rotation step may be included for simplicity or consistency) and, in Step #2, the dry analyte deposit 216 is re- suspended in the first aliquot of liquid yielding a known dilution similar to that obtained when the device is used to run a sample of the same concentration, using the acceleration and decceleration described above to promote mixing and resuspension.
  • resuspension may instead occur in the second dilution in step #3.
  • the position of the analyte deposit 216 may be varied.
  • the deposit 216 may be disposed in block D in a chamber corresponding to unvented chamber 204 in block C.
  • the rotational protocol may be identical or substantially the same for the assay and quality control runs of the respective devices.
  • the reader 400 comprises a drive 402 under control of a controller 404 for controlling a rotation profile of a device 100 in the drive and having a spindle 406 for engaging the feature 1 14 as the device is loaded into the reader, for example in the manner of CD or DVD disk loading tray.
  • a light source 408 is configured to shine light onto or through the detection chamber 1 12 of the device 100 when loaded into the reader and a sensor 410 is configured to receive light from the detection chamber 1 12 as described above.
  • a processor 412 is connected to the sensor 410 to process a signal indicative of the received light to carry out the assays or perform quality control or calibration.
  • a method of quality control or calibration implemented by the processor 412 and controller 404 (or the processor 412 controlling the other components of the reader 400) is now described with reference to Figure 5.
  • a device 100 is loaded.
  • the drive is controlled to implement a rotation protocol to implement the assay with the device and at step 506 a signal is read and processed to obtain an assay result, for example a concentration of analyte.
  • the reader checks whether the device is a quality control device, for example by detecting a machine-readable indicium on the device 100 or by way of a user input, for example entered prior to inserting the device and stored. If it is not, the reader reports the result of the assay via a user interface (not shown) at step 510.
  • the reader compares the obtained assay result with an expected result to perform quality control or calibration at step 514.
  • the expected result may be stored in the reader, for example in firm ware, may be entered by a user when providing an input indicating a quality control device, or may read by the reader from the or another machine- readable indicium.
  • Quality control may comprise determining if the obtained result is within an acceptable margin of the expected result and calibration may comprise adjusting a parameter of the reader, for example calibration data used by the reader to obtain the assay result, so that the obtained result matches the expected result.
  • the device is manufactured by forming the liquid handling structures (channels, conduits, etc.) in a substrate, for example by injection moulding or stamping the substrate. The substrate is then sealed by bonding a polymer film to the surface in which the liquid handling structures are defined, with appropriate cut-outs for fluidic access to the liquid handling device.
  • the device may be formed by bonding together two substrates, which may both define respective liquid handling structures, for example, in cooperation, or by a sandwich of a bonding film between two substrates.
  • the deposit of analyte may be applied to the device by first applying drops of solution or suspension containing the reagent(s) to the relevant substrate, in the region which, once the substrate is bonded with its counterpart (either the polymer film or another substrate), will form the appropriate structure, for example the unvented chamber 204.
  • the drops of solution or suspension are then allowed to dry, thus leaving behind the dry reagent(s) on the substrate.
  • a solution containing the one or more reagents may be applied to a body of absorbent material, which is then allowed to dry, leaving behind dry reagent(s) on the material.
  • the material can then be disposed on the substrate, in the region which will form the appropriate structure, prior to or after the substrate has been bonded with its counterpart.
  • conduits have been described above with reference to drawings depicting channel shaped conduits, it will be understood that the term “conduit” covers any arrangement providing a flow path conveying or conducting liquid from one part of the device to another.
  • a conduit with a bend or crest for example as described above for the flow control device 212 can, for example, be implemented as a bent channel as depicted schematically in the drawings, or more generally as any structure that can contain liquid, has an inlet, and an outlet and is shaped or configured so that liquid flowing from the inlet to the outlet first flows radially outward (or, respectively, inward) to an inflection point and then flows radially inward (or, respectively, outward).
  • conduits (and other flow paths) described herein in various embodiments are thus defined by their function and a shape or configuration necessary to achieve that function, rather than being limited to any specific shape or configuration beyond that which is necessary to achieve the respective described functions.
  • chambers have been described above with reference to drawings depicting chambers of a certain form factor, it will be appreciated that the disclosure is not so limited and that the described chambers may take any suitable shape or configuration, for example have varying depth, be significantly elongate to resemble a channel, for example a serpentine or meandering channel, be formed by a network of channels or cavities, contain pillars, comprise interconnected volumes, etc.
  • Embodiments have been described with reference to microfluidic devices, specifically centrifugal microfluidic devices, but it will be apparent that the concept of integrating a quality control sample in an assay device for later reconstitution is not limited to any particular device or flow mechanism but is, for example, equally applicable to embodiments with other flow mechanisms, for example pressure, gravity, electrophoresis, electro osmosis, chromatographic and so on driven flow. It will be appreciated that the disclosure extends to all such embodiments and is also not limited to any specific way of manufacturing the devices or any specific form factor. Likewise, the disclosure is not limited to the specific assays, analytes and reagents described here but extends to all assays that can benefit from an arrangement that enables reconstitution of an integrated quality control sample, be that for the purpose of quality control or calibration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)

Abstract

L'invention concerne un dispositif de contrôle de qualité et un procédé de fabrication d'un lot de dispositifs de dosage comprenant un dispositif de contrôle de qualité, ainsi qu'un procédé d'utilisation du dispositif de contrôle de qualité pour réaliser un contrôle de qualité. Par exemple, l'invention concerne un dispositif conçu pour effectuer un dosage pour détecter un analyte avec un réactif. Le dispositif comprend le réactif, un liquide et un dépôt de l'analyte. Le dispositif est conçu pour permettre à un échantillon comprenant l'analyte à une concentration connue d'être reconstitué avec le liquide et pour permettre la détection d'un dosage de l'analyte à l'aide du réactif.
PCT/EP2018/067162 2017-06-30 2018-06-26 Dispositif de contrôle de qualité intégré Ceased WO2019002321A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1710490.2A GB201710490D0 (en) 2017-06-30 2017-06-30 Integrated quality control device
PT110174 2017-06-30
PT110174B 2017-06-30
GB1710490.2 2017-06-30

Publications (1)

Publication Number Publication Date
WO2019002321A1 true WO2019002321A1 (fr) 2019-01-03

Family

ID=62749000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/067162 Ceased WO2019002321A1 (fr) 2017-06-30 2018-06-26 Dispositif de contrôle de qualité intégré

Country Status (1)

Country Link
WO (1) WO2019002321A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957890A1 (fr) * 2014-06-16 2015-12-23 Roche Diagnostics GmbH Cartouche avec couvercle rotatif

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957890A1 (fr) * 2014-06-16 2015-12-23 Roche Diagnostics GmbH Cartouche avec couvercle rotatif

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"How to perform a Spinit CRP test?", 1 June 2016 (2016-06-01), Retrieved from the Internet <URL:http://www.axonlab.com/CZ_eng/Primary-care/Human-medicine/Clinical-chemistry/spinit-R-One-Instrument> [retrieved on 20180717] *
ANONYMOUS: "Instructions for use. For in-vitro diagnostic.", 1 March 2015 (2015-03-01), XP002783146, Retrieved from the Internet <URL:http://www.poct.co.uk/products/pdfs/CR014-15_PL-001-05_Instructions%20for%20Use_11-reference%20only.pdf> [retrieved on 20180717] *
ANONYMOUS: "One instrument haematology immunoassays clinical chemistry", SPINIT, 1 June 2016 (2016-06-01) - 1 June 2016 (2016-06-01), pages 1 - 4, XP002783147, Retrieved from the Internet <URL:http://www.axonlab.com/CZ_eng/Primary-care/Human-medicine/Clinical-chemistry/spinit-R-One-Instrument> [retrieved on 20180717] *
ANONYMOUS: "Vision-based blood test system delivers results in 15 minutes", 10 September 2012 (2012-09-10), XP002783145, Retrieved from the Internet <URL:https://www.vision-systems.com/articles/2012/09/vision-based-blood-test-system-delivers-results-in-15-minutes.html> [retrieved on 20180717] *
O. STROHMEIER ET AL: "Centrifugal microfluidic platforms: advanced unit operations and applications", CHEMICAL SOCIETY REVIEWS, vol. 44, no. 17, 1 January 2015 (2015-01-01), pages 6187 - 6229, XP055423852, ISSN: 0306-0012, DOI: 10.1039/C4CS00371C *

Similar Documents

Publication Publication Date Title
US7459127B2 (en) Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces
KR101431769B1 (ko) 당화 혈색소 측정용 원심력 기반의 미세유동 구조물, 당화 혈색소 측정용 원심력 기반 미세유동 장치 및 당화 혈색소의 측정방법
JP5023043B2 (ja) 反応可変要素の特徴付け
EP2529220B1 (fr) Dispositif microfluidique centrifuge et procédé de détection de substances à analyser dans échantillon liquide
EP2133150B1 (fr) Dispositif d&#39;étiquetage sur disque
CN108136397B (zh) 确定血液样品中的分析物的量的方法以及医疗系统
EP2175278B1 (fr) Dispositif pour analyse, et appareil et procédé utilisant le dispositif
US20040121449A1 (en) Method and apparatus for separation of particles in a microfluidic device
WO2021243882A1 (fr) Puce microfluidique et appareil de détection in vitro
JP2013541013A (ja) ある液体量を部分量に配分するためのマイクロ流体試験担体
JP7163558B2 (ja) 分離装置及び分離方法、分離デバイス、並びに検査装置及び検査方法
EP4292712A1 (fr) Puce microfluidique
CN211652892U (zh) 一种离心式检测卡
TWI385383B (zh) 分析系統及其分析方法、流路結構
CN106489072A (zh) 具有计量室的用于分析生物样品的旋转筒
CN112770842A (zh) 用于引导液体通过多孔介质的设备和方法
Gubala et al. Simple approach to study biomolecule adsorption in polymeric microfluidic channels
CN118122400A (zh) 一种离心式干式生化检测微流控芯片及其使用方法
Wan et al. Rapid parallel blood typing on centrifugal microfluidic platform by microcolumn gel immunoassay
WO2019002321A1 (fr) Dispositif de contrôle de qualité intégré
EP3532202A1 (fr) Cartouche d&#39;essai de diagnostic de point d&#39;intervention
CN111443194A (zh) 免疫检测方法
WO2018077983A1 (fr) Cartouche d&#39;essai de diagnostic de point d&#39;intervention
CN101603896B (zh) 分析系统及其分析方法、流路结构
CN215843043U (zh) 用于血型检测的微流控检测装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18734222

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18734222

Country of ref document: EP

Kind code of ref document: A1